Kossel Medical Successfully Completes Over RMB 100 Million Financing to Advance Peripheral Intervention Pipeline and Global Expansion

VCBeat (WeChat: vcbeat) learned第一时间 that recently, Kossel Medtech (Suzhou) Co., Ltd. (hereinafter referred to as Kossel Medical) has successfully completed a financing round exceeding 100 million yuan. This round of financing was led by Ming Bioventures and Yue Yin Healthcare Fund, with LC Future following up.

This round of financing will help Kossel Medtech enrich its peripheral product pipeline, build a one-stop treatment product system in the field of peripheral intervention, expand production bases, and attract more high-end talents.

Kossel Medtech (Suzhou) Co., Ltd. is located in Suzhou Science and Technology City, China. The company was founded in November 2013 and is a platform enterprise with comprehensive production and R&D capabilities for vascular interventional devices, dedicated to providing systematic solutions for clinical use. Kossel Medtech is a national high-tech enterprise, with nearly 10,000 square meters of R&D and production base, equipped with professional R&D and testing laboratories. It possesses systematic independent innovation R&D capabilities and leading production and manufacturing capabilities, and has already obtained nearly a hundred intellectual property rights.

Kossel's innovative product in the peripheral field, the vena cava filter, has been successfully registered and commercialized. It is the first umbrella-shaped long-term filter approved for registration in China. Several other innovative products are about to enter clinical trials. In the coronary field, the balloon products have obtained registration certificates from China's NMPA, the U.S. FDA, the EU CE, Japan's PMDA, and South Korea's KFDA, and have entered the international mainstream market.

This round of financing was led by Ming Bioventures and Yue Yin Datong(tianjin)asset Management Co.,Ltd., both of which have extremely rich experience in medical industry investment, fully demonstrating that the investment value of Kossel Medtech has been recognized by professional institutions.

Kossel Medtech CEO Qing HuKossel Medtech stated that it will remain true to its original aspiration, always bear in mind the mission of "developing excellent products, serving human health, and benefiting more patients," adhere to the principles of "cooperation and sharing," continuously serve clinical needs, and contribute to the development of China's medical device industry. This round of financing will also undoubtedly help Kossel Medtech grow faster and better.

Dr. Pang Xiubing, Partner of Ming BioventuresKossel Medtech is a platform enterprise with comprehensive production and R&D capabilities in vascular interventional devices. After years of accumulation and deep integration of medical engineering, its product pipeline is quite extensive, covering coronary intervention, peripheral intervention, and cardiac electrophysiology. It also provides OEM/ODM technical services for various implantable metal stents, interventional balloons, and catheters. Ming Bioventures hopes that through this round of investment cooperation, it can help Kossel Medtech develop into a leading company with global competitiveness.

Ms. You Linlin, Vice President of Investment Department, Yue Yin Healthcare FundCongratulations to Kossel Medtech on successfully completing a new round of financing. As a key segment in the healthcare sector, the peripheral intervention field has seen rapid market demand growth and boasts a rich product pipeline, making it a focal point for Yue Yin Healthcare Fund. Kossel Medtech, a leader in this field, was the first to receive approval for China's first umbrella-shaped long-term filter. Its R&D pipeline contains a diverse range of products, positioning the company as one of the few domestic enterprises capable of providing one-stop solutions for peripheral interventions. The company has accumulated extensive process expertise and possesses large-scale manufacturing capabilities. We believe that Kossel Medtech will continue to bring innovative and cost-effective products to patients in the future. Though the road ahead is long and fraught with challenges, progress will come with perseverance. Yue Yin Healthcare Fund will continue to keep a close eye on Kossel Medtech and looks forward to contributing further to the development of the healthcare industry alongside Kossel Medtech.

Ming Bioventures Focuses on Early-Stage Investments in Innovative Drugs, Emerging Biotechnologies, and Medical Devices (Including Diagnostics), Supporting Entrepreneurs to Meet the Many Unmet Clinical Needs. Since its establishment in October 2018, Ming Bioventures has invested in more than 40 companies.

Yue Yin Datong (Tianjin) Asset Management Co., Ltd., one of the most professional medical investment institutions recognized in the industry, is committed to finding the most innovative and growth-oriented healthcare teams in China, becoming the "capital" partner of enterprises. Since its establishment in 2015, it has invested in more than 30 outstanding companies across various subfields of healthcare, and has been honored with multiple awards including "Golden Investment Award · Top 30 Best Healthcare Investment Institutions in China 2021," "Top 100 Best Venture Capital Institutions in China 2020" by ChinaVenture, and "Top 20 Best Medical Device Investment Institutions in China 2020."